Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
Abstract CYP3A5 is the primary CYP3A subfamily enzyme expressed in the human kidney and its aberrant expression may contribute to a broad spectrum of renal disorders. Pharmacogenetic studies have reported inconsistent linkages between CYP3A5 expression and hypertension, however, most investigators h...
Guardado en:
Autores principales: | Kevin A. Lidberg, Andrew J. Annalora, Marija Jozic, Daniel J. Elson, Lu Wang, Theo K. Bammler, Susanne Ramm, Maria Beatriz Monteiro, Jonathan Himmelfarb, Craig B. Marcus, Patrick L. Iversen, Edward J. Kelly |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a3c201a0a7084bb899171d4e7331ae73 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Author Correction: Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
por: Kevin A. Lidberg, et al.
Publicado: (2021) -
Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy
por: Niels Grote Beverborg, et al.
Publicado: (2021) -
Induction of cryptic pre-mRNA splice-switching by antisense oligonucleotides
por: Kristin A. Ham, et al.
Publicado: (2021) -
Fluorescent base analogues in gapmers enable stealth labeling of antisense oligonucleotide therapeutics
por: Jesper R. Nilsson, et al.
Publicado: (2021) -
Tritium labeling of antisense oligonucleotides via different conjugation agents
por: Martin R. Edelmann, et al.
Publicado: (2021)